Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2012

Jan 11, 2012

29977_dirs_2012-01-11_65f26e66-2545-4c69-b7e7-ab2238ddd2a8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-01-10

Reporting Person: Terifay Robert J (SVP Commercial)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-01-10 Common Stock M 18128 $21.34 Acquired 27500 Direct
2012-01-10 Common Stock F 5233 $73.92 Disposed 22267 Direct
2012-01-10 Common Stock F 4651 $73.92 Disposed 17616 Direct
2012-01-10 Common Stock M 1872 $21.92 Acquired 19488 Direct
2012-01-10 Common Stock F 554 $73.92 Disposed 18934 Direct
2012-01-10 Common Stock F 543 $73.92 Disposed 18391 Direct
2012-01-11 Common Stock S 9019 $74.2 Disposed 9372 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-01-10 Non-Qualified Stock Option (right to buy) $21.34 M 18128 Disposed 2017-02-26 Common Stock (18128) Direct
2012-01-10 Non-Qualified Stock Option (right to buy) $21.92 M 1872 Disposed 2017-12-17 Common Stock (1872) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1387 Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 9,019 shares of Company stock on January 11, 2012 at prices ranging from $74.10 to $74.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 11, 2012 at each separate price.

F3: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F4: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

F5: The stock option award vests in four equal annual installments, commencing one year after the date of grant.